Today we will be discussing risks associated with platelet transfusions for patients with rare, immune-mediated platelet consumptive disorders.
Thrombotic thrombocytopenic purpura, or TTP, is a life-threatening condition characterized by the formation of clots in small blood vessels throughout the body. Heparin-induced thrombocytopenia, or HIT, is a rare and severe reaction to heparin that leads to platelet activation and thrombin formation. Immune thrombocytopenic purpura, or ITP, causes less serious bleeding and bruising, and usually resolves without treatment.
Using the Nationwide Inpatient Sample database, a new study reviewed nearly 100,000 hospital records of patients with TTP, HIT and ITP.
Here is Dr. Takemoto, who is one of the study authors:
“Because these conditions are so rare, hematologists have little to go on when deciding how to treat them. Some data suggests that transfusions may be harmful for these patients.”
Data on platelet transfusions for patients with TTP, HIT and ITP is currently lacking. Nevertheless, researchers found that 10% of TTP patients, 7% of HIT patients and 26% of ITP patients received platelet transfusions.
Platelet transfusions, however, were associated with adverse events for many of these patients.
Dr. King, who is another study author, explains:
“Platelet transfusions increased the odds of dying in the hospital five-fold for patients with HIT and doubled the odds for patients with TTP, even after adjusting for age and gender. Arterial thrombosis was also higher in patients with TTP and HIT who received a platelet transfusion. We found no associations for ITP patients and platelet transfusions.”
Platelet transfusions are commonly administered to sicker patients who are bleeding. However, the results remained significant after adjusting for clinical severity.
Until further studies are available, Dr. Takemoto advises:
“Platelet transfusions should be used only for emergencies: invasive procedures, surgeries or severe bleeding in TTP and HIT patients. For HIT patients, the first step is to stop administering heparin and.for TTP patients,plasma exchange therapy should be initiated.”
We’ll be back with another edition of Transfusion News on February 15. Thanks for joining us.
Reference
Dr. Ken Groshart says
Agree. Would include aHUS, APAS (tho unusual to get platelet counts below 40-50K unless catastrophic transition) and HELLP syndrome (personal experience with one case only)
Reuben Wafula Welanunu says
True, platelet transfusion and / or any component transfusions should only be administered after carefully weighing the transfusion benefits Versus the potential harm to the recipient.
lisa says
yes. I have TTP, I WAS DIAGNOSED IN JULY 2013. I WAS DOING FINE UNTIL 1YR. AND A , HALF LATER I COULD NOT FORM A SENTENCE SO I HAD MY BLOOD CHECKED MY PLATELETS WERE AT 9,000 I WAS IN DEEP TROUBLE I WAS BACK IN THE HOSP. 4 DAYS,OUT OF HOSP THEN THE VERY NEXT WEEK WAS BACK IN THE HOSPITAL, FOR 2 WEEKS THREW XMAS And went home on new years eve….I got a long journey ahead and will accept all ,and any advise that is helpful to my situation rightnow I am on chemo drug called vinacristine I have already been on rituxin that only teased my blood my no. were up and now my ADAMST13 IS LESS THAN 3